Recovery and Survival of Buffy Coat-Derived Platelets Stored for 7 Days in Plasma or Additive Solution

被引：0
|
作者：
Cardigan, R. [1 ]
Cooke, L. [1 ]
Cookson, P. [2 ]
Wiltshire, M. [2 ]
Williamson, L. M. [1 ]
机构：
[1] NHS Blood & Transplant, Cambridge, England
[2] NHS Blood & Transplant, Brentwood, Essex, England
来源：
TRANSFUSION | 2009年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：86A / 86A
页数：1
相关论文
共 50 条
  • [31] Generation of procoagulant coat platelets in stored platelet-concentrate units derived from buffy-coat preparations
    Calderara, D. B.
    Crettaz, D.
    Barelli, S.
    Tissot, J-D
    Lion, N.
    Prudent, M.
    Alberio, L.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 652 - 652
  • [32] Extended storage of buffy coat platelet concentrates in plasma or a platelet additive solution
    Slichter, Sherrill J.
    Bolgiano, Doug
    Corson, Jill
    Jones, Mary Kay
    Christoffel, Todd
    Bailey, S. Lawrence
    Pellham, Esther
    TRANSFUSION, 2014, 54 (09) : 2283 - 2291
  • [33] Whole blood platelet rich plasma derived pools stored in additive solution preserve good function to 7 days
    Sweeney, JD
    Kouttab, NM
    Cheves, TA
    Kurtis, JD
    Nelson, EJ
    Holme, S
    TRANSFUSION, 2005, 45 (03) : 30A - 31A
  • [34] In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology
    Ostrowski, Sisse R.
    Bochsen, Louise
    Salado-Jimena, Jose A.
    Ullum, Henrik
    Reynaerts, Inge
    Goodrich, Raymond P.
    Johansson, Par I.
    TRANSFUSION, 2010, 50 (10) : 2210 - 2219
  • [35] Treatment of Buffy Coat Platelets in Platelet Additive Solution with the Mirasol® Pathogen Reduction Technology System
    Castrillo, Azucena
    Cardoso, Marcia
    Rouse, Lindsay
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2013, 40 (01) : 44 - 48
  • [36] Hemostatic Function of Buffy Coat Platelets in Additive Solution Treated with Mirasol Pathogen Reduction Technology
    Ostrowski, S. R.
    Bochsen, L.
    Salado-Jimena, J. A.
    Ullum, H.
    Reynaerts, I.
    Goodrich, R. P.
    Johansson, P. I.
    TRANSFUSION, 2009, 49 : 97A - 98A
  • [37] MIRASOL® PATHOGEN REDUCTION TECHNOLOGY TREATMENT OF ORBISAC BUFFY COAT PLATELETS SUSPENDED IN ADDITIVE SOLUTION
    Maia, S.
    Rio, N.
    Marques, S.
    Rouse, L.
    VOX SANGUINIS, 2010, 99 : 245 - 246
  • [38] Cryopreserved buffy-coat-derived platelets reconstituted in platelet additive solution: A safe and available product with sufficient haemostatic effectiveness
    Lejdarova, Hana
    Pacasova, Rita
    Tesarova, Lenka
    Koutna, Irena
    Polokova, Nadezda
    Michlickova, Simona
    Dolecek, Martin
    TRANSFUSION AND APHERESIS SCIENCE, 2021, 60 (03)
  • [39] STORAGE OF BUFFY-COAT-DERIVED PLATELETS IN ADDITIVE SOLUTIONS: IN VITRO EFFECTS ON PLATELETS PREPARED BY THE NOVEL TACSI SYSTEM AND STORED IN PLASTIC CONTAINERS WITH DIFFERENT GAS PERMEABILITY
    Sandgren, P.
    Hild, M.
    Sjodin, A.
    Gulliksson, H.
    VOX SANGUINIS, 2010, 99 : 191 - 191
  • [40] In vitro variables of buffy coat-derived platelet concentrates with residual plasma of down to 10% are stably maintained in new-generation platelet additive solutions
    Gravemann, Ute
    Volgmann, Thorsten
    Min, Kyungyoon
    Philipp, Roman
    Lambrecht, Bernd
    Mueller, Thomas H.
    Seltsam, Axel
    TRANSFUSION, 2015, 55 (07) : 1700 - 1709
12345